An investigational study to learn whether regular healthcare, combined with early treatment with a cholesterol lowering drug called evolocumab (Repatha®) reduces heart attack, stroke, procedures to improve blood flow, and death, compared to regular healthcare alone.
Contact phoneSparrow Clinical Research Institute | 517.364.5760
Principal investigatorDr. Chad Link, DO, FACC
Trial CategoryHeart & Vascular
Trial SubCategoryLipid Management